VRB-102 / Sciwind Biosci, Verdiva Bio - LARVOL DELTA

Preclinical and formulation characterisation of a novel amylin analog VRB-102 designed for co-formulation with a GLP-1 receptor agonist for the treatment of obesity and type 2 diabetes (ECO 2026) - "Overall, VRB-102 demonstrated a PK profile compatible with once weekly dosing and in vitro hAMY3 and hCTR activation comparable to cagrilintide. In preclinical animal models, combination of VRB-102 with GLP-1RA VRB-101 induced greater body weight reduction that was at least additive compared to the individual peptides. Moreover, VRB-102 could be co-formulated with VRB-101 at pH 7.4, potentially enabling storage and delivery of both drugs from a single chamber injection device."

Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio (PRNewswire) - "Hangzhou Sciwind Biosciences...today announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited ('Verdiva')...The partnered portfolio under this collaboration includes: Oral Ecnoglutide (Ecnoglutide Oral, XW004): A phase 2-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist. Oral Amylin Receptor Agonist (Amylin RA): A potential first-in-class, once-weekly long-acting, oral amylin receptor agonist in IND-enabling studies. Subcutaneous injectable Amylin Receptor Agonist (Amylin RA): A potential best-in-class, long-acting, amylin receptor agonist in IND-enabling studies....Under the agreement, Sciwind receives an upfront consideration totaling approximately $70 million, and is eligible to receive more than $2.4 billion in milestone payments for development,..."

Licensing / partnership • Metabolic Disorders • Obesity